TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)

Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H. Al Ali, Aref Al-Kali, Kebede H. Begna, James M. Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Padron, David A. Sallman, Animesh Pardanani, Daniel A. Arber, Attilio Orazi, Kaaren K. Reichard, Rong He, Rhett P. Ketterling, Naseema GangatRami Komrokji

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Among 210 patients with myelodysplastic syndromes (MDSs) with del(5q), molecular information was available at diagnosis or at least 3 months before leukaemic transformation in 146 cases. Multivariate analysis identified therapy-related setting (p = 0.02; HR 2.3) and TP53 variant allele frequency (VAF) ≥22% (p < 0.01; HR 2.8), but not SF3B1 mutation (p = 0.65), as independent risk factors for survival. Median survival was 11.7 versus 4 years (5/10-year survival 73%/52% vs. 42%/14%) in the absence (N = 112) versus presence (N = 34) of ≥1 risk factors; leukaemia-free survival was affected by TP53 VAF ≥22% (p < 0.01). Such information might inform treatment decision-making in MDS-del(5q) regarding allogeneic stem cell transplant.

Original languageEnglish
JournalBritish Journal of Haematology
Publication statusPublished or Issued - 25 Dec 2023
Externally publishedYes


  • SF3B1
  • cytogenetics
  • mutation
  • prognosis
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this